Hydroxyurea treatment for chronic myeloid leukemia during pregnancy
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, cilt.79, sa.9, ss.803-804, 2000 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 79 Sayı: 9
- Basım Tarihi: 2000
- Doi Numarası: 10.1034/j.1600-0412.2000.079009803.x
- Dergi Adı: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.803-804
- Anahtar Kelimeler: chronic myeloid leukemia, hydroxurea treatment, white blood cell count
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75,000. Several types of treatments have been used for CML during pregnancy. These are cytotoxic drugs, alpha-interferone, splenic irradiation (with shielding of the uterus) and leukapheresis. Hydroxyurea is a cytotoxic drug that inhibits the synthesis of DNA and can be used both in the chronic and accelerated phases of CML (1).